Identification of Circulating miR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis

Cellular Physiology and Biochemistry

Volumn 39, Issue 5, 2016, Pages 1716-1722

  Deng, Ting ^a   Yuan, Yaozong ^b   Zhang, Chunni ^c   Zhang, Chenyu ^c   Yao, Weiyan ^b   Wang, Cheng ^c   Liu, Rui ^a   Ba, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

Biomarker; Circulating microRNAs; MiR 25; Pancreatic cancer; Serum

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MICRORNA; MICRORNA 25; UNCLASSIFIED DRUG; MIRN25 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC PANCREATITIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; AGED; AREA UNDER THE CURVE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; EARLY DIAGNOSIS; GASTROINTESTINAL NEOPLASMS; GENETICS; METABOLISM; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; ROC CURVE;

EID: 84988568699     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447872     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403.
3. Hidalgo M: Pancreatic cancer. N Engl J Med 2010;362:1605-1617.
4. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327.
5. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS: MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311:392-404.
6. Buchsbaum DJ, Croce CM: Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? JAMA 2014;311:363-365.
7. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009;2:807-813.
8. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W, Kong X: Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012;131:683-691.
9. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY: Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012;58:610-618.
10. Marchi S, Pinton P: Mitochondrial calcium uniporter, MiRNA and cancer: Live and let die. Commun Integr Biol 2013;6:e23818.
11. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z: MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep 2012;27:594-598.
12. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179.
13. Tang F, Hajkova P, Barton SC, Lao K, Surani MA: MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006;34:e9.
14. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014;20:460-469.
15. Sun XJ, Liu BY, Yan S, Jiang TH, Cheng HQ, Jiang HS, Cao Y, Mao AW: MicroRNA-29a Promotes Pancreatic Cancer Growth by Inhibiting Tristetraprolin. Cell Physiol Biochem 2015;37:707-718.
16. Song B, Zheng K, Ma H, Liu A, Jing W, Shao C, Li G, Jin G: miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Cell Physiol Biochem 2015;35:1846-1856.
17. Song B, Zhang C, Li G, Jin G, Liu C: MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem 2015;35:1167-1177.
18. Song W, Li Q, Wang L, Wang L: Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem 2015;35:184-190.
19. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT: Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013;32:61-69.
20. Jang JY, Lee YS, Jeon YK, Lee K, Jang JJ, Kim CW: ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma. Exp Mol Med 2013;45:e3.
21. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M: Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011;10:3-8.
22. Chen F, Hu SJ: Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 2012;26:79-86.
23. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, Wu W, Wu XZ: MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One 2011;6:e27008.
24. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-743.
25. Schonleben F, Qiu WL, Ciau NT: PIK-3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006;12:3851-3855.
26. Yu J, Li A, Hong SM, Hruban RH, Goggins M: MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 2012;18:981-992.
27. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010;3:109-113.
28. Dai X, Pang W, Zhou Y, Yao W, Xia L, Wang C, Chen X, Zen K, Zhang CY, Yuan Y: Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus. J Diabetes 2016;8:422-433.
29. Ballehaninna UK, Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012;3:105-119.
30. Goldstein MJ, Mitchell EP: Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23:338-351.
31. Kennedy BK, Smith ED, Kaeberlein M: The enigmatic role of Sir2 in aging. Cell 2005;123:548-550.